Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Wasa Medical Holdings v. Sorrento Therapeutics, Inc. et al
Case Number:
3:20-cv-00966
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Bragar Eagel
- Kirby McInerney
- Levi & Korsinsky
- Paul Hastings
- Pomerantz LLP
- Robbins Geller
- Wolf Haldenstein
Companies
Sectors & Industries:
-
November 19, 2021
Sorrento Escapes COVID-19 Investor Class Action
A California federal judge has dismissed a proposed class action from investors in Sorrento Therapeutics Inc. who claimed the company misled the public about its COVID-19 treatment, finding the investors didn't adequately show how the company's statements were misleading.
-
February 16, 2021
Robbins Geller To Lead Sorrento COVID-19 Class Action
Robbins Geller Rudman & Dowd LLP will represent a proposed class of investors in Sorrento Therapeutics Inc. in a federal suit in San Diego alleging that the company misled the public after its CEO characterized some of its COVID-19 research as a "cure."
-
August 13, 2020
Sorrento Investors Fight To Lead COVID-19 'Cure' Suit
Sorrento Therapeutics Inc. investors represented by Pomerantz, Kirby McInerney and Robbins Geller continue to fight for appointment as lead plaintiff in a proposed securities class action accusing the company of misleading the public after its CEO characterized some of its COVID-19 research as a "cure."
-
May 29, 2020
COVID-19 Securities Catch-Up: The 8 Biggest Investor Actions
At least 50 federal securities cases with references to COVID-19 have been filed in the past three months, including merger challenges, regulatory enforcement actions and sprawling investor suits, according to a Law360 review of filings. As the pandemic pushes into the summer, Law360 is taking a look at eight major investor actions that were brought in connection with the novel coronavirus since March.
-
May 27, 2020
Sorrento Sued Over COVID-19 'Cure' Comment To Fox News
Sorrento Therapeutics Inc. was hit with a stock-drop suit on Tuesday over statements its CEO made to Fox News in mid-May that allegedly referred to a recent breakthrough in the company's COVID-19 treatment research as a "cure."